AlphaFold predicted structure
SETD1B · Q9UPS6

Mean pLDDT
45.5/ 100
Very low
1,966 residues
Confidence breakdown
- Very high(≥ 90)9%
- Confident(70–90)11%
- Low(50–70)6%
- Very low(< 50)74%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
SET domain containing 1B, histone lysine methyltransferase
Annotations refreshed 1 month ago.
Diagnostic Grade (Green)
DDG2P
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownEarly onset or syndromic epilepsy
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedIntellectual disability
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedintellectual developmental disorder with seizures and language delay
hereditary disease
neurodevelopmental disorder
autosomal dominant non-syndromic intellectual disability
complex neurodevelopmental disorder
Abnormality of the skeletal system
epilepsy
escherichia coli infection
Neurodevelopmental delay
lung adenocarcinoma
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Histone-lysine N-methyltransferase SETD1B
Histone methyltransferase that catalyzes methyl group transfer from S-adenosyl-L-methionine to the epsilon-amino group of 'Lys-4' of histone H3 (H3K4) via a non-processive mechanism (PubMed:17355966, PubMed:25561738). Part of chromatin remodeling machinery, forms H3K4me1, H3K4me2 and H3K4me3 methylation marks at active chromatin sites where transcription and DNA repair take place (PubMed:17355966, PubMed:25561738). Plays an essential role in regulating the transcriptional programming of multipotent hematopoietic progenitor cells and lymphoid lineage specification during hematopoiesis (By similarity)
SETD1B · Q9UPS6

Mean pLDDT
45.5/ 100
Very low
1,966 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0